Zonisamide

Overview

Zonisamide is a sulfonamide anticonvulsant medication primarily used to treat partial seizures in adults. It works by inhibiting sodium channels and reducing current through T-type calcium channels, which stabilizes neuronal activity.

API suppliers (18)

Suppliers of Zonisamide evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• COHANCE LIFESCIENCES LTDIndia2 active DMF GMP on record
• ALIVUS LIFE SCIENCES LTDIndia2 active DMF GMP on record
• MAITHRI DRUGS PRIVATE LTDIndia1 active DMF GMP on record
• EMNAR PHARMA PRIVATE LTDIndia1 active DMF
• Unichem Laboratories Ltd.India1 active DMF GMP on record
• Sun Pharmaceutical Industries LimitedIndia1 active DMF GMP on record
• Dipharma Francis SrlItaly1 active DMF GMP on record
• Hetero Labs LimitedIndia1 active DMF GMP on record
• Zydus Lifesciences LimitedIndia1 active DMF GMP on record
• Wockhardt UsaUnited Kingdom1 active DMF
• PERRIGO API LTD
• JUZEN CHEMICAL CORPJapan
• MYLAN LABORATORIES LTD GMP on record
• Teva Pharmaceutical Industries Ltd.Israel GMP on record
• APOTEX PHARMACHEM INC
• BACHEM INCSwitzerland GMP on record
• DR REDDYS LABORATORIES LTD GMP on record
• PROCOS SPAItaly GMP on record

Patent & exclusivity (US)

Per the FDA Orange Book (24 approved US products), the latest listed US patent on Zonisamide expires 18 Aug 2038. Generic API sourcing typically opens up once these lapse.

Therapeutic areas